TF and gastrointestinal stromal tumor: We also tested whether TF targeting in the CCLE melanoma cell lines was associated with response to regorafenib, a multi-kinase inhibitor that has been approved for treating metastatic colorectal cancer, advanced gastrointestinal stromal tumors, and advanced hepatocellular carcinoma.